Korro Bio, Inc. SEC filings KRRO

Korro Bio, Inc. has 830 filings in SEC EDGAR's recent list, going back to Apr 14, 2017. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (agreement ended, results of operations). The company's fiscal year ends on December 31.

Korro Bio, Inc. SEC filings
Form Description Filed Period
DEFA14A Additional proxy material Apr 16, 2026 —
DEF 14A Proxy statement Apr 16, 2026 Jun 10, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 11, 2025
DEFA14A Additional proxy material May 1, 2024 —
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 11, 2024
PRE 14A Preliminary proxy statement Apr 19, 2024 Jun 11, 2024
DEFA14A Additional proxy material Apr 29, 2022 —
DEF 14A Proxy statement Apr 29, 2022 Jun 21, 2022
DEFA14A Additional proxy material Apr 29, 2021 —
DEF 14A Proxy statement Apr 29, 2021 Jun 17, 2021
DEFA14A Additional proxy material Apr 29, 2020 —
DEF 14A Proxy statement Apr 29, 2020 Jun 11, 2020

Showing 14 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KRRO (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1703647
Former names
Frequency Therapeutics, Inc. (until Nov 6, 2023)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.